Enabling drug discovery through

cutting-edge AI technologies



To be a global leader integrating Biotech and AI



To build a healthier world and to make innovative medicines accessible

About Us

Galixir is a biotech company that drives drug discovery on with AI.

Galixir is leveraging AI to streamline drug research, focusing on hard-to-develop drugs and unmet clinical needs.

Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Pyxir®, the AI-driven drug discovery platform of Galixir, leverages cutting-edge AI algorithms to resolve problems in the preclinical development of small molecule drugs and to find candidate molecules with high potency, good druggability and novel structures. M1, the intelligent computing platform of Galixir combining AI with classical physics principles, makes breakthroughs in classical molecular modeling methods at the world’s top level. It is able to accurately describe the interactions between molecules and proteins, and predict the binding free energy between target drug molecules and specific targets with high efficiency and accuracy.

Galixir has identified two novel preclinical compounds candidate (PCC) for autoimmune diseases through Pyxir® and M1 platform, demonstrating its AI drug discovery capabilities in a closed loop. Galixir will continue to take “AI-driven drug discovery pipeline” and “AI-driven computing platform” as the dual cycle to empower drug discovery, in a bid to build a healthier world and to make new drugs accessible.

About UsAbout Us

Our Team Members

are from worldwide top-tier universities, first-rate Internet companies and renowned pharmaceutical enterprises

Galixir team members have rich experience in leading drug discovery projects to IND and FDA approval, and machine learning application experience in top-tier Internet companies including Google, Apple and Microsoft. Besides, Galixir has already published 30+ papers in top journals and conference proceedings, covering subjects including molecular generation, property prediction and virtual screening and so forth. And our models have kept the world performance record.

Galixir works together with domestic and oversea universities and research institutions including Georgia Institute of Technology, Massachusetts Institute of Technology, University of Pennsylvania, Google Brain of Google AI, Mila, Guangzhou Institutes of Biomedicine and Health of Chinese Academy of Science, Institute of Microbiology of Chinese Academy of Science, Shanghai Jiao Tong University, Zhejiang University and Sun Yat-sen University.

Our History

Establishment of Galixir
Establishment of Shanghai office
Collaboration established with Guangzhou Supercomputing Center, leveraging the "Tianhe-2" supercomputer to aid AI and computational chemistry tool development
Construction of a large-scale hybrid Cloud Computing Platform to support AI model development
Launch of the AI-driven drug R&D platform, Pyxir®
Galixir's team won the grand championship of the "Innovation Master Cup" Cryo-EM protein structure modeling contest with an absolute advantage
The AI-powered Pyxir® platform played a significant role in the progression of preclinical candidate molecules (PCC) nomination, positioning Galixir at the forefront of the industry
Launch of TankBind, the world's first deep learning framework that simultaneously predicts both small-molecule drug binding conformation and binding affinity
The independently developed General Force Field, GFF, and Galixir Free Energy Perturbation, GFEP, reached world-class accuracy and were opened for testing
Recognized as a Beijing Science and Technology Small and Medium-sized Enterprise
Two papers on PROTAC and retrosynthetic analysis were published in Nature Machine intelligence and Nature Communications
Launch of the AI-driven computational platform, M1®, for drug discovery and design
Recognized as a National High-tech Enterprise
The AI-driven computational platform, M1®, launched high-throughput docking and intelligent molecular recommendation features
Launch of the world's first protein dynamic docking model, GDynamic (DynamicBind), charting a new course for the computational discovery of cryptic pockets
Galixir now operates in three offices/labs across the country, with multiple drug R&D pipelines actively progressing



Galixir joins hands with our partners from circles of academy,industry and investment to boost the digitalization and intelligence of new drug discoveryand write a new chapter for drug discoveryAnd more undisclosed partners......